Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00393861 · ClinicalTrials.gov registry record · Phase 2
Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT00393861 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 29 participants.
The verdict
NCT00393861, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of oxaliplatin and bevacizumab in patients with refractory or relapsed germ cell tumors.
Interventions
- DRUG Bevacizumab and Oxaliplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2006-10 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00393861
The ClinicalTrials.gov registry entry for NCT00393861 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Bevacizumab and Oxaliplatin is the first listed.
NCT00393861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00393861 about?
NCT00393861 is a clinical study titled "Study of Oxaliplatin Plus Bevacizumab in Germ Cell Tumor Patients". The purpose of this study is to evaluate the effectiveness of oxaliplatin and bevacizumab in patients with refractory or relapsed germ cell tumors.
What is the current status of trial NCT00393861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2006-10. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00393861?
The interventions under investigation include: Bevacizumab and Oxaliplatin (DRUG).
Who is sponsoring clinical trial NCT00393861?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.